

PEER-REVIEW REPORT

Name of journal: World Journal of Meta-Analysis

Manuscript NO: 61346

Title: Nusinersen, an exon 7 inclusion drug for spinal muscular atrophy: A minireview

Reviewer's code: 05993664

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Hungary

Author's Country/Territory: India

Manuscript submission date: 2020-12-03

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-03-26 16:12

Reviewer performed review: 2021-03-29 14:44

Review time: 2 Days and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The title correctly indicates the nature of the paper. The abstract gives a succinct summary on the characteristics of the drug. Although the description of the characteristics, especially of the basic research results of nusinersen is not very detailed, it is scientifically correct. This shortage is acceptable since the expected audience are clinicians. On the other hand, the lack of a description of other registered drugs for treating SMA makes the paper one sided. In order to appreciate the significance of nusinersen for the clinical practice, at least the clinical results of the gene therapy Zolgensma and the newly registered risdiplam (Evrysdi) should be mentioned. Their clinical advantages and disadvantages should be shortly discussed compared to nusinersen. Such comparative discussion is needed for the medical community. The authors only mention that the drug is registered by FDA. Nusinersen has broad international marketing authorization in many countries. The very high price of nusinersen are above the accepted pharmacoeconomic limits in many countries, not only in the US. Finally I suggest that when presenting data on different motor functions comparing point values on specific scales, it would be very helpful if the authors would shortly describe what do these functional scale differences represent in actual motor function for the patients.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Meta-Analysis

Manuscript NO: 61346

Title: Nusinersen, an exon 7 inclusion drug for spinal muscular atrophy: A minireview

Reviewer's code: 05993664

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Hungary

Author's Country/Territory: India

Manuscript submission date: 2020-12-03

Reviewer chosen by: Jia-Ping Yan

Reviewer accepted review: 2021-05-24 07:08

Reviewer performed review: 2021-05-24 07:13

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The discussion was extended providing a well balanced view on the therapeutic place of

Nusinersen in the treatment of SMA.